Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancerWei Wei, Rong Zhang, Xin Huang et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 38
Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.Wei Wei, Min Zheng, Xiaohua Ban et al.|Journal of Clinical Oncology|2021Cited by 2
Detection of molecular signatures of homologous recombination deficiency in endometrial cancer (180)Xiaqin Cheng, Jundong Li, Wei Wei et al.|Gynecologic Oncology|2022Cited by 0